The CHANCE-3 trial showed that in patients with minor-to-moderate IS or TIA and high-sensitivity C-reactive protein levels ≥2 mg/L, early initiation of colchicine (0.5 mg b.i.d. on days 1–3, followed by 0.5 mg o.d. thereafter) was not superior to placebo in reducing the risk of subsequent stroke within 90 days (HR 0.98; 0.83–1.16; P = 0.79).68 However, the short follow-up and the lower limit 95% CI of the HR suggest that sustained treatment may be required for secondary prevention. The gene discussed is CRP; the disease is stroke disorder.